Atlanta,
GA -- June 11, 2019
-- InvestorsHub NewsWire -- via Emerging MicroCaps
--
-
Last year, US
Nuclear shares (now
$1.00) spiked to $5
when they announced an
exclusive
partnership with MIFTEC and a
revolutionary new way to
make and supply billions of dollars of medical radioisotopes at
half today's cost to a $10 Billion industry that is suffering from
severe shortages and high costs.
-
Powerful
neutron flux is required to produce radioisotopes and
50-year-old,
unreliable, costly and hazardous fission reactors have been the
primary source of neutron flux.
-
Recently,
the
leading Fusion
Energy Science Journal,
peer reviewed,
investigated, verified, and
reported US
Nuclear's
partner
MIFTEC, achieved major
milestone of
1010
neutron flux from
fusion power at UNR
TeraWatt
Facility
proving that their radical new fusion technology works exactly as
predicted and can make billions of dollars of high-quality
radioisotopes for
half the current cost.
-
MIFTEC hired a
leading nuclear fusion design engineer from a National Lab and has
already completed design plans for the first commercial 10 Mega
Ampere
LTD-X (linear
transformer driver) Staged Z-Pinch Fusion Generator that can be
built in between 1 and 2 years, and US Nuclear is now looking for
locations to build MIFTEC's Fusion Generators.
-
US Nuclear is
highly respected provider of technical
products to the military and other demanding
customers and enjoys
strong
growth and
potential for strong price appreciation. Only 17
million shares outstanding of which about 10 million are closely
held by management.
-
When news about
this discovery was announced last year, US Nuclear shares spiked to
$5 per share. Now that their multi-billion-dollar discovery has
been confirmed by the leading fusion energy journal, and
their
machine
is
ready to be
built, shares are highly undervalued with
potential to soon shatter previous highs by
several multiples.
Overview
Medical
radioisotopes are essential for accurately diagnosing cancer and
heart disease and for treating about half of all
cancers.
Unfortunately
for cancer and
heart patients, a
multi-billion-dollar annual
shortage of radioisotopes is
predicted to worsen
because over 90% of radioisotopes
are made in only 5 nuclear
fission reactors that are unreliable because they are about 50
years old and subject to frequent unpredictable
shutdowns. These 5 nuclear
reactors are all outside the United States and not practical owing
to the very short life of around 6 hours for the
isotopes and the time-consuming
distances they must travel to get to
the end
user. Additionally,
these nuclear fission reactors cost
billions of dollars
to replicate, they can take over a decade to build, they
require
radioactive uranium as fuel that is extremely hazardous and that
requires very costly handling and disposal.
To
help ease the shortage, there is a current effort underway to build
smaller and cheaper reactors in the United States using Low
Enriched Uranium, but the extremely high cost
of disposing of any high enriched uranium or low enriched
uranium will
continue to perpetuate
high prices and it will still take several years for these
smaller reactors to
come on line. Some
of
the better known competitors using
the
new
twist of Low
Enriched Uranium that is still the same old costly and hazardous
fission technology are
Northstar,
Shine,
Niowave,
and Northwest Medical.
In fact, it is likely that the use of LEU will be even more
expensive than HEU because of the more frequent handling and
disposal.
In
spite of all efforts, the
shortage is predicted
to last until a
revolutionary technical
breakthrough is discovered
to be able to make radioisotopes from some other
lower
cost and safer source.
How
radioisotopes
are
made
While a small
number of radioisotopes occur naturally, by far the greatest
percentage is made from neutrons that are produced in nuclear
fission reactors. Cyclotrons and particle accelerators
also produce
neutrons but only
in
very small
quantities that are not practical.
Any
powerful source of
neutrons can be used to produce radioisotopes.
US Nuclear Corp's (OTC: UCLE) exclusive partner,
MIFTEC/MIFTI (Magneto Inertial Fusion Technologies) Achieves
Revolutionary Breakthrough
Recently,
the leading
Fusion Energy Science Journal
reported that MIFTI/MIFTEC technology
achieved
1010
power
in neutron
flux at the University of Nevada, Reno Terawatt Facility (UNR/NTF)
in experiments using a 1 Mega Ampere machine. Results were
confirmed by an independent laboratory. This is a feat never before
accomplished by a privately held company in the history of fusion
science. These important results were peer reviewed, investigated
for confirmation, and published in Physics of
Plasmas May 2019 issue.
Because the
current flow of 1 Mega Ampere limited neutron production to close
to
1010
on the UNR
machine, MIFTI/MIFTEC quickly moved forward and already completed
design plans for a larger 10 Mega Ampere machine that is
predicted to generate
1015
in neutrons
that
is well in excess of the
1012
required for the production
of radioisotopes. US Nuclear has
already announced
that they are now
searching for the best cities to build their new
generators.
US Nuclear, MIFTI
and MIFTEC agree that a conservative estimate for the time to build
the first commercial generator will probably take less than 24
months, but are giving themselves extra time for potential delays
that are unknown. The companies are weighing various locations and
funding options and once they have made a decision leading to
completion of funding and location for the first machine,
construction will commence.
Why UCLE and MIFTEC will dominate the $10 Billion Medical
Radioisotope Industry
-
Most
importantly because UCLE/MIFTEC will be able to deliver the highest
quality medical radioisotopes in enormous quantities at
HALF PRICE!
-
The
LTD-X
Staged Z-Pinch
Fusion Generator will be
very low cost to build and
operate compared to
all other competition.
-
The
LTD-X
Staged Z-Pinch
Fusion Generator is very
small and can fit in a hospital or medical center where the
Radioisotopes will be used.
-
No long-term hazardous nuclear waste.
When asked what
the biggest milestone achievements have been since they first
announced their breakthrough technology last year, Jerry Simmons
said,
"In the second half of last year we did what nobody else has ever
been able to do. Not even the big government projects. We made
history by generating Neutron Flux in excess of 1010
from fusion power using an isotope of hydrogen from seawater
instead of radioactive enriched uranium. This proves beyond any
doubt that our machine can make the isotopes used in nuclear
medicine (i.e. Mo-99, Tc-99m, cobalt 60, iodine, etc.). It is only
a matter now of simply scaling the power or electric current flow
of our machine up so we can achieve the greater Neutron Flux
of 1012+.
Dr. Hafiz Rahman, President and Chief Scientist and his staff at
MIFTEC Labs and the University of Nevada, Reno National Terawatt
Facility, tells us that our scientific experimental predictions and
the device will work as designed."
Dr. Hafiz
Rahman says,
"To give you an idea of how advanced we are, when we achieve
1015,
it will be 10,000,000,000 (ten billion) times more powerful than
105.
That is more than enough power to create all the Neutron Flux we
need to supply low cost radioisotopes and power for production of
electricity with our compact, low cost machines."
Simmons
continuing,
"The machine we used at University of Nevada, Reno National
Terawatt Facility was a 1 MA (1 Mega Amp) machine which limited the
Neutron Flux we could generate to 1010.
Last year, we hired a top nuclear design engineer and he has
already completed the design for our new 10 MA (10 Mega Amps) LTD-X
Staged Z-Pinch Fusion Generator that is designed to generate
1015
Neutron
Flux that is extremely powerful and matches or exceeds the high
power of the fission reactors being used today for radioisotope
production. Our new generators are small and will fit into a
building close to where the radioisotopes will be used. Our
generators will be only a tiny fraction of the cost of the huge
nuclear fission reactors and linear accelerators, and there will be
no long-term hazardous radioactive waste to contend with that is
dangerous and extremely expensive. Nuclear fission reactors can
cost anywhere from several hundred million dollars to several
billion dollars and we estimate that our machine will
sell for around 5 million
dollars. Our Staged Z-Pinch LTD-X Fusion Generator will be small
and compact and will require very few people to operate. The bottom
line is that we will be able to deliver enormous amounts of
high-quality radioisotopes for about half today's cost."
About Bob Goldstein and Jerry Simmons
Bob Goldstein,
the CEO of US Nuclear, graduated from MIT with a degree in Physics
and has a degree in Engineering from Stanford. He has authored more than 40
white papers and presentations on radiation measurement and his
work has been met and approved by US Federal standards set by the EPA,
FDA, and NRC. He also works closely with
Los Alamos, Sandia and Jefferson National Labs.
His family's first experiences
in
nuclear physics
go back to the 1940's when his
father was involved in the historic Manhattan Project that
developed the atomic bomb.
Mr. Goldstein
founded US Nuclear and is known for delivering the most sensitive,
accurate and reliable instruments in the world. The quality of
their work is confirmed by a list of loyal and repeat customers
such as NASA, the EPA, Department of Energy, U.S. Air Force, U.S.
Army, U.S. Navy, MIT, Pacific Gas & Electric, General Electric,
Lawrence Livermore, Oakridge National Lab and many more.
Jerry Simmons
is the only person in the world who has founded two fusion energy
companies. In 1998, Mr. Simmons co-founded Tri-Alpha Energy that is
a now a multi-billion-dollar company with big early investors such
as Paul Allen's Vulcan Investments and Art Samburg's
hedge fund.
The company is now called TAE Technologies. Jerry also co-founded
Magneto-Internal Fusion Technologies, Inc. (MIFTI) and MIFTEC
Laboratories, Inc. Mr. Simmons is very experienced and well
connected with government officials that are interested in nuclear
fusion based power and radioisotopes that are produced from fusion
power sources. Mr. Simmons has negotiated a work package between
MIFTEC Laboratories and Oak Ridge National Laboratory.
About US Nuclear
US
Nuclear has enjoyed a long-standing financial history of stable
sales and profitability, but in 2017 demand for US
Nuclear's
products began
increasing and has continued at a high growth rate since. Several
new large opportunities are blossoming in the underserved
radioisotope market, and the environmental monitoring market that
is
forecast to hit $20
billion by 2021. For example, China is converting all of their
coal-fired power plants that are responsible for dangerous polluted
air and water, to about 200 fission nuclear reactors that all
require the best radiation monitoring equipment in order to insure
safety. The Chinese nuclear agency claims that each individual
nuclear power plant requires about $8,000,000 in the highest
quality and most reliable radiation monitoring devices and has
already met with Mr. Goldstein twice last year with the intention
of purchasing large orders of US Nuclear monitoring equipment. With
World Nuclear Power Organization's
forecast for a growing
number of nuclear power plants to produce electricity (none planned
to produce radioisotopes), the demand for radiation monitoring
devices also grows.
Other
large opportunities for US Nuclear are their unique products
recently offered for radon mitigation in homes and offices and the
use of drones to mount their sophisticated monitoring devices.
Radon is commonly found in many homes and is one of the leading
known causes of lung cancer. Goldman Sachs sees the
drone market growing
to a very large size by 2020. Drones are the perfect vehicle for
carrying US Nuclear environmental monitoring devices for public
safety and for national security threats of terrorism that could
impact our air or water.
In
conclusion, US Nuclear is enjoying strong growth from its core
business, and on top of that, is well positioned to become a major
supplier in a multi-billion-dollar healthcare market of
radioisotopes.
Goldstein
says,
"Given the failing state of essential medical isotope production
facilities, this
first-ever achievement to meet and exceed the 1010
milestone
in fusion neutron production could not come at a better time.
Additionally, the projected cost savings of up to 50% over the
current imported resources; the idea of on-site production; the low
cost and shorter time to build the generators, and the
environmental benefit of a non-proliferating process that precludes
the hazards of fission-based methods; should make for important
upgrades ahead in the vital medical isotope supply chain."
Conclusion
US Nuclear
reports only 17 million shares outstanding translating to a very
small market cap of about $20 million. Of the 17 million shares
outstanding, management owns about ten million shares. The float is
small and based on a number of metrics including sales, the share
price is substantially undervalued. Any investor looking at US
Nuclear should run the numbers for themselves and calculate what
the shares could be valued at if their sales
mushroomed
to the large numbers that the radioisotope business can
bring. The big question is, "How much of a $10 Billion-dollar
market (that is expected to be $17 Billion in 2021), can US Nuclear and MIFTEC
own if they can deliver valuable, high demand radioisotopes
at
half-price?
And if US Nuclear generates billion dollar sales with only 17
million shares outstanding, how high will the price go?
With the best science, the best solution, and the capability to
deliver high quality radioisotopes at half the current cost, it
seems likely that UCLE and MIFTEC can capture at least 50% of the
$7 billion shortage and a similar amount of the $10 billion
supply. Running the numbers suggests very lofty
prices.
US Nuclear shares
appear to be a bargain and poised for record highs
in the not too distant future.
Legal
Disclaimer:
Except for the
historical information presented herein, matters discussed in this
release contain forward-looking statements that are subject to
certain risks and uncertainties that could cause actual results to
differ materially from any future results, performance or
achievements expressed or implied by such statements.
Emerging
MicroCaps
or its
principals may have been compensated for its
services in the form of cash-based compensation or equity
securities in the companies it writes about. The Information contains
forward-looking statements, i.e. statements or discussions that
constitute predictions, expectations, beliefs, plans, estimates, or
projections as indicated by such words as ''expects,'' ''will,''
''anticipates,'' and ''estimates''; therefore, you should proceed
with extreme caution in relying upon such statements and conduct a
full investigation of the Information and the Profiled Issuer as
well as any such forward-looking statements.
June
11,
2019
Emerging
MicroCaps
Atlanta,
GA
EmergingMicroCaps.com
US
Nuclear Corp. (UCLE)
Grafico Azioni US Nuclear (PK) (USOTC:UCLE)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni US Nuclear (PK) (USOTC:UCLE)
Storico
Da Gen 2024 a Gen 2025